Sorafenib in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase I trial is studying the side effects, such as high blood pressure, and
best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor.